Trovagene Eyes $6.1M in Public Offering
January 31, 2013
Trovagene Eyes $6.1M in Public Offering
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer
April 26, 2013 / GenomeWeb Daily News - Trovagene's Q4 Revenues, Loss Rise
April 2, 2013 / GenomeWeb Daily News - Dx Focus: Trovagene's HPV-HR Assay; BioTheranostics' CancerType ID
March 28, 2013 / PCR Insider - Trovagene, MD Anderson Partner on Transrenal BRAF Mutation Detection
January 3, 2013 / PCR Insider - Trovagene Set to Offer Transrenal KRAS Assay on Bio-Rad dPCR System in January
November 29, 2012 / PCR Insider